晚期上皮性卵巢癌的扩散加权MRI:表观扩散系数作为疗效反应标志物
这项前瞻性多中心试验(2012-2016年)纳入125例晚期上皮性卵巢癌、原发性腹膜癌或输卵管癌患者(新诊断47例,复发78例),评估扩散加权MRI的表观扩散系数(ADC)作为疗效反应、无进展生存期(PFS)和总生存期的指标;结果显示三个周期铂类化疗后ADC变化提示疗效反应,一个周期后ADC升高提示复发疾病PFS改善。
要点
- 基线ADC可重复,95%一致性界限上限为12×10⁻⁵mm²s⁻¹,下限为-15×10⁻⁵mm²s⁻¹。
- 三个周期后,生化反应定义下反应者ADC变化百分比为16.6% vs 无反应者3.9%(P=0.02)。
- 三个周期后,影像学反应定义下反应者ADC变化百分比为19.0% vs 无反应者6.2%(P=0.04)。
核心结论
- 三个周期铂类化疗后,ADC变化提示疗效反应;一个治疗周期后ADC升高提示复发疾病PFS改善;ADC变化对总生存期无提示作用。
研究设计与样本
- 前瞻性多中心试验(2012-2016年),纳入125例(中位年龄63.3岁,四分位距57.0-70.7岁;均为女性;队列一47例,队列二78例)III或IV期卵巢、原发性腹膜或输卵管癌患者,队列一为新诊断并计划铂类化疗及间歇性减瘤手术,队列二为复发;队列一基线与0-7天后两次MRI评估ADC可重复性,三个治疗周期后追加MRI;队列二基线及一个和三个治疗周期后成像;采用Wilcoxon秩和检验比较反应者与无反应者ADC变化,多变量Cox模型评估PFS和总生存期。
诊断标准与关键数值
- 基线ADC范围77-258×10⁻⁵mm²s⁻¹,可重复性95%一致性界限上限12×10⁻⁵mm²s⁻¹(95%CI:6×10⁻⁵mm²s⁻¹至18×10⁻⁵mm²s⁻¹),下限-15×10⁻⁵mm²s⁻¹(95%CI:-21×10⁻⁵mm²s⁻¹至-9×10⁻⁵mm²s⁻¹)。
- 队列二一个治疗周期后47%患者ADC升高;三个周期后队列一58%、队列二53%患者ADC升高。
- 三个周期后反应者与无反应者ADC较基线变化百分比:生化反应定义16.6% vs 3.9%(P=0.02);影像学反应定义19.0% vs 6.2%(P=0.04)。
- 队列二一个周期后ADC升高与PFS延长相关(校正HR=0.86,95%CI:0.75-0.98,P=0.03)。
局限性
- ADC变化对两个队列的总生存期均无提示作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Treatment of advanced epithelial ovarian cancer results in a relapse rate of 75%. Early markers of response would enable optimization of management and improved outcome in both primary and recurrent disease. Purpose To assess the apparent diffusion coefficient (ADC), derived from diffusion-weighted MRI, as an indicator of response, progression-free survival (PFS), and overall survival. Materials and Methods This prospective multicenter trial (from 2012-2016) recruited participants with stage III or IV ovarian, primary peritoneal, or fallopian tube cancer (newly diagnosed, cohort one; relapsed, cohort two) scheduled for platinum-based chemotherapy, with interval debulking surgery in cohort one. Cohort one underwent two baseline MRI examinations separated by 0-7 days to assess ADC repeatability; an additional MRI was performed after three treatment cycles. Cohort two underwent imaging at baseline and after one and three treatment cycles. ADC changes in responders and nonresponders were compared (Wilcoxon rank sum tests). PFS and overall survival were assessed by using a multivariable Cox model. Results A total of 125 participants (median age, 63.3 years [interquartile range, 57.0-70.7 years]; 125 women; cohort one, n = 47; cohort two, n = 78) were included. Baseline ADC (range, 77-258 × 10-5mm2s-1) was repeatable (upper and lower 95% limits of agreement of 12 × 10-5mm2s-1 [95% confidence interval {CI}: 6 × 10-5mm2s-1 to 18 × 10-5mm2s-1] and -15 × 10-5mm2s-1 [95% CI: -21 × 10-5mm2s-1 to -9 × 10-5mm2s-1]). ADC increased in 47% of cohort two after one treatment cycle, and in 58% and 53% of cohorts one and two, respectively, after three cycles. Percentage change from baseline differed between responders and nonresponders after three cycles (16.6% vs 3.9%; P = .02 [biochemical response definition]; 19.0% vs 6.2%; P = .04 [radiologic definition]). ADC increase after one cycle was associated with longer PFS in cohort two (adjusted hazard ratio, 0.86; 95% CI: 0.75, 0.98; P = .03). ADC change was not indicative of overall survival for either cohort. Conclusion After three cycles of platinum-based chemotherapy, apparent diffusion coefficient (ADC) changes are indicative of response. After one treatment cycle, increased ADC is indicative of improved progression-free survival in relapsed disease. Published under a CC BY 4.0 license. Online supplemental material is available for this article.
引用
- Winfield JM, Wakefield JC, Dolling D, et al. Diffusion-weighted MRI in Advanced Epithelial Ovarian Cancer: Apparent Diffusion Coefficient as a Response Marker. Radiology. 2019. PMID: 31573402. doi:10.1148/radiol.2019190545
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。